New hope for PCV: higher-dose eye injection may reduce treatment burden
NCT ID NCT07365371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a stronger dose (8 mg) of the drug aflibercept in Chinese patients with polypoidal choroidal vasculopathy (PCV), a type of wet age-related macular degeneration that can cause rapid vision loss. About 174 people who have not been treated before will receive three monthly eye injections, then be assigned to one of two retreatment schedules based on disease activity. The goal is to see if the higher dose can improve vision and keep the disease under control with fewer visits and injections over one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Eye Hospital of Nanchang University
Nanchang, Jiangxi, China
-
Affiliated Hospital Of Shandong Second Medical University
Weifang, Shandong, China
-
Beijing Hospital
Beijing, Beijing Municipality, China
-
Beijing Tongren Hospital, CMU
Beijing, Beijing Municipality, China
-
Eye & ENT Hospital of Fudan University
Shanghai, Shanghai Municipality, China
-
Jiangsu Province Hospital , The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
-
Jiaxing Hospital of T.C.M
Jiaxing, Zhejiang, China
-
Renmin Hospital Of Wuhan University
Wuhan, Hubei, China
-
Shandong Provincial Hospital
Jinan, Shandong, China
-
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
-
Shanxi Eye Hospital
Taiyuan, Shanxi, China
-
The First Affiliated Hospital Of Harbin Medical University
Harbin, Heilongjiang, China
-
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunan, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
-
The First People's Hospital Of Xianyang
Xianyang, Shaanxi, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
The Second Norman Bethune Hospital Of Jilin University
Jilin City, Jilin, China
-
The Second People's Hospital Of Foshan
Foshan, Guangdong, China
-
Tianjin Eye Hospital
Tianjin, Tianjin Municipality, China
-
Xi' AN No.1 Hospital
Xi'an, Shaanxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.